A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial

[1] Navarini AA(2017)European consensus statement on phenotypes of pustular psoriasis J Eur Acad Dermatol Venereol 31 1792-1799

[2] Burden AD(2004)Prevalence of symptoms experienced by patients with different clinical types of psoriasis Br J Dermatol 151 594-599

[3] Capon F(2009)Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool J Am Acad Dermatol 60 1024-1031

[4] Mrowietz U(2006)Measuring quality of life of patients with different clinical types of psoriasis using the SF-36 British Journal of Dermatology 154 844-849

[5] Puig L(2012)Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity Nat Genet 44 1341-1348

[6] Köks S(2014)Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial J Eur Acad Dermatol Venereol 28 1298-1305

[7] Kingo K(2006)Interventions for chronic palmoplantar pustulosis Cochrane Database Syst Rev 1 CD001433-636

[8] Smith C(2017)British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 British Journal of Dermatology 177 628-2639

[9] Barker JN(2013)Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris J Invest Dermatol 133 2637-437

[10] Sampogna F(2011)Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis Am J Hum Genet 89 432-628

[1] Navarini AA(2017)European consensus statement on phenotypes of pustular psoriasis J Eur Acad Dermatol Venereol 31 1792-1799

[2] Burden AD(2004)Prevalence of symptoms experienced by patients with different clinical types of psoriasis Br J Dermatol 151 594-599

[3] Capon F(2009)Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool J Am Acad Dermatol 60 1024-1031

[4] Mrowietz U(2006)Measuring quality of life of patients with different clinical types of psoriasis using the SF-36 British Journal of Dermatology 154 844-849

[5] Puig L(2012)Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity Nat Genet 44 1341-1348

[6] Köks S(2014)Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial J Eur Acad Dermatol Venereol 28 1298-1305

[7] Kingo K(2006)Interventions for chronic palmoplantar pustulosis Cochrane Database Syst Rev 1 CD001433-636

[8] Smith C(2017)British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 British Journal of Dermatology 177 628-2639

[9] Barker JN(2013)Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris J Invest Dermatol 133 2637-437

[10] Sampogna F(2011)Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis Am J Hum Genet 89 432-628